Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos
exposure and associated with a very poor prognosis. After more than a decade without new …

Simple Summary Immune checkpoint inhibitors (ICIs) have emerged as a very promising
therapeutic option for the treatment of many difficult-to-treat cancers and a number of clinical …

Malignant pleural mesothelioma (MPM) is a tumor with a poor prognosis, whose incidence is
increasing worldwide due to widespread previous exposure to asbestos. Only few patients …

Background The role of immunotherapy in cancer is now well-established, and therapeutic
options such as checkpoint inhibitors are increasingly being approved in many cancers such …

Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, with a
poor prognosis as the majority of patients are diagnosed with unresectable MPM, with no …

Malignant pleural mesothelioma (MPM) is considered a relatively uncommon disease but its
incidence is increasing worldwide. Patients affected by MPM have a very severe prognosis …

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with low survival rates.
Platinum-based chemotherapy has represented the cornerstone of treatment for over a …

Platinum-based chemotherapy is commonly used as the standard first-line treatment for
unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune …

Unresectable malignant pleural mesothelioma (MPM) is an aggressive disease with a 5-
year survival rate of approximately 10%. Recent data suggest that MPM is an …

Simple Summary This review article will focus on the landmark studies that came to define
current treatment paradigms for malignant pleural mesothelioma (MPM), all the way from …